Healthcare Services
Human Papillomavirus (HPV) Testing Market

Human Papillomavirus (HPV) Testing Market Size, Share, and Growth Forecast for 2025-2032

Q: How big is the human papillomavirus (HPV) testing industry?

The market is set to reach US$ 1,400 Mn in 2025.

Q: What is the future outlook of the human papillomavirus (HPV) testing industry?

The industry will likely be valued at US$ 2,816 Mn in 2032.

Q: What is the projected growth rate of the human papillomavirus (HPV) testing industry?

The industry is set to surge at a CAGR of 10.5% through 2032.

Human Papillomavirus (HPV) Testing Market by Product (DNA-based Test, RNA-based Test), Application (Molecular Diagnostics, Research Use), End User (Hospitals, Clinics, Diagnostics Centers, Research Institutes), and Regional Analysis

ID: PMRREP11737

April 2025

192 Pages

Author : Vaishnavi Patil

Healthcare

Preview Segmentation

Human Papillomavirus (HPV) Testing Market Size and Trends

The global human papillomavirus (HPV) testing market size is anticipated to rise from US$ 1,400 Mn in 2025 to US$ 2,816.3 Mn by 2032. It is projected to witness a CAGR of 10.5% from 2025 to 2032.

Human papillomavirus (HPV) testing is a diagnostic procedure used to detect the presence of high-risk HPV strains that can lead to cervical cancer and other HPV-related diseases. The demand for HPV tests globally is experiencing an uptick on account of the increasing cases of cancer and mortality. According to the American Cancer Society, in 2025, approximately 2,041,910 new cancer cases and 618,120 cancer deaths are estimated to occur in the U.S.

It is to be noted that cervical cancer is the fourth most common cancer form in women and needs attention. Global health agencies and national governments are focusing on cervical cancer prevention initiatives through screening, vaccination, and treatment, which is anticipated to favor the market growth through 2032.

As per this Persistence Market Research report, companies such as Abbott Laboratories, Thermo Fischer Scientific Inc., Qiagen N.V., and others are focusing on introducing innovative products, investments in research and development, and leveraging technological advancements to maintain a stronghold in the market.

human papillomavirus testing market outlook, 2019-2032

Key Highlights

On the basis of product, the DNA-test segment is projected to hold a market share of about 62.4% in 2025. The increasing preference for primary HPV screening in countries such as the U.S., Australia, and others.
Based on application, the molecular diagnostics segment is likely to hold a market share of about 87.4% in 2025. The dominance of the segment is attributable to the increasing adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) owing to their accuracy and reliability.
Based on region, North America is anticipated to dominate and hold a share of about 40.3% in 2025. Factors such as the presence of prominent healthcare companies and the availability of advanced diagnostic technologies are driving the demand for the market during the forecast period.
Companies in the market are focusing on adopting a collaborative approach to introduce innovative HPV testing solutions.
Increasing prevalence of HPV-related cancer cases globally is anticipated to boost the demand for human papillomavirus (HPV) testing market through 2032.

Global Market Attributes	Key Insights
Human Papillomavirus Testing (HPV) Market Size (2025E)	US$ 1,400 Mn
Market Value Forecast (2032F)	US$ 2,816.3 Mn
Projected Growth (CAGR 2025 to 2032)	10.5%
Historical Market Growth (CAGR 2019 to 2024)	8.9%

Historical Growth and Course Ahead

Historical Period Witnessed Increasing Number of Screenings in Emerging Economies

In the historical period from 2019 to 2024, the global market for human papillomavirus (HPV) testing showcased a CAGR of 8.9%.

The onset of COVID-19 severely impacted the HPV vaccination programs globally. Since 2019, HPV vaccination coverage dropped at an alarming rate of 15%. This represented one of the most significant drops in any vaccine during the pandemic. Further, as per UNICEF, in 2020, around 600,000 new cervical cancer cases and 340,000 deaths were reported. 90% of these cases and deaths occurred in low and middle-income countries, where people had limited access to prevention, screening, and treatment services.

However, to improve the situation, agencies such as UNICEF focused on working closely and partnering with vaccine manufacturers to provide a steady supply and availability of HPV vaccination in emerging countries. The growing demand for HPV screening and prevention led to a significant improvement in early detection of cases globally. For instance,

The International Agency for Research on Cancer (IARC) reported a 25% rise in HPV screening participation in low- and middle-income countries (LMICs) between 2019 and 2023, showcasing the impact of public health initiatives and technological innovations.

Positive Future Outlook: Collaborative Approach by Companies to Develop Innovative Testing Products

The global human papillomavirus (HPV) testing market is likely to showcase a CAGR of 10.5% from 2025 to 2032. Technological advancements in telemedicine and the adoption of collaborative strategies by healthcare companies are likely to boost the market. For instance,

In February 2025, Metropolis Healthcare, one of India’s leading pathology lab chains, collaborated with Roche Diagnostics to introduce the self-sampling HPV DNA test for cervical cancer screening. This collaboration is aimed at improving the early detection of cancer cases through easy access towards the screening process, especially for women living in Tier 2, Tier 3, and Tier 4 cities.

The increasing preference for HPV self-collection testing, which enables collecting samples from any location as per convenience, is empowering women to take control of their health.

Get Your CustomizationGet Your Customization

Market Dynamics

Growth Drivers

Increasing Prevalence of HPV-Linked Cancers to Boost Demand for Early Screening

HPV is a major cause of cancer globally, including cervical, anal, oropharyngeal, vaginal, penile, and vulvar, among others. Cervical cancer is the most common HPV-associated cancer type among women, and oropharyngeal cancer is the most common among males. According to the U.S. Centers for Disease Control and Prevention (CDC), every year in the United States, around 47,984 new cancer cases are discovered in parts of the body where HPV is commonly found. Of these, 37,800 cancers are caused due to HPV.

The increasing prevalence of HPV-linked cancers is driving the demand for screening, testing, and treatment procedures, which is anticipated to drive market growth during the forecast period.

Market Restraining Factors

Frequent Changes in Screening Guidelines to Impede Market Growth

The American Cancer Society’s (ACS) cervical cancer screening guidelines advise commencing HPV testing at age 25 and repeating it every 5 years. Or using a pap test every 3 years, or a combo of HPV/pap test every 5 years. However, frequent revisions to guidelines such as those concerning screening intervals and initiation ages may lead to confusion among healthcare providers and public. Moreover, as vaccination coverage increases, HPV prevalence is expected to decline, initiating further changes to screening guidelines. This factor may affect the demand for HPV testing to a certain extent during the forecast period.

To mitigate the risk of lower screening compliance rates, it is important for policymakers to effectively communicate guidelines and evidence of benefits to women and healthcare workers.

Key Market Opportunity

Integration of HPV Testing with Other Diagnostic Tools to Create New Avenues for Market Players

Integrating HPV testing with other diagnostic tools enhances cancer screening by improving accuracy, reducing follow-up losses, and providing customized approaches to different clinical settings. Established companies like Roche Diagnostic, BD, Qiagen, Abbott, and others are focusing on introducing advanced triage options consisting of extended genotyping and dual-stain cytology. For example, Roche Diagnostic’s HPV screening platform helps to detect HPV16, HPV18, and 12 other high-risk HPV specimens.

Approvals for human papillomavirus (HPV) testing procedures by government agencies are further propelling the companies to introduce advanced diagnostic solutions. For instance, the Roche Cobas HPV test is the only HPV test approved by the Food and Drug Administration (FDA) for primary cervical cancer screening in the United States. The test is approved for use with both ThinPrep and SurePath liquid-based cytology specimens.

Human Papillomavirus (HPV) Testing Market Insights

Product Insights

Growing Preference for Primary HPV Screening to Propel Demand for DNA-based Tests

Based on product, the DNA-based test segment is projected to hold a market share of about 62.4% in 2025. The segment is further forecasted to witness considerable growth, backed by growing preference for HPV DNA testing as a primary screening tool, replacing or supplementing Pap smears in countries such as the U.S., Australia, and others. DNA-based tests such as PCR (Polymerase Chain Reaction) and Hybrid Capture 2 are more reliable than traditional Pap smears in detecting high-risk HPV strains, while reducing false negatives. Further, increasing public awareness campaigns and preventive healthcare initiatives have led to more women opting for DNA-based tests, which is anticipated to drive the segmental growth during the forecast period.

Application Insights

Technological Advancements in PCR & Next-Gen Sequencing (NGS) to Surge Demand for Molecular Diagnostics

On the basis of application, the molecular diagnostics segment is expected to dominate and hold a human papillomavirus (HPV) testing market share of about 87.4% in 2025. The dominance of the segment is attributable to the increasing demand for real-time PCR and NGS technologies due to their accuracy, scalability, and efficiency in HPV testing and other disease detection. For instance, NGS allows parallel sequencing of thousands of DNA fragments, making it ideal for large-scale HPV screening programs.

End User Insights

Availability of Centralized Diagnostic Facilities to Drive Demand for Hospitals Globally

Based on end user, the hospital segment is expected to register a market share of about 53.5% in 2025. The dominance of the segment is attributed to the availability of advanced diagnostic technologies, high patient volumes, comprehensive care offerings, and regulatory support. Hospitals provide both routine screenings and diagnostic tests while managing the treatment and follow-up care of HPV-related conditions.

human papillomavirus testing market insights and key trends

Request Free sampleRequest Free sample

Regional Insights and Trends

North America Human Papillomavirus (HPV) Testing Market

Availability of Robust Diagnostic Capabilities to Spur Product Demand

North America is projected to hold the major revenue share of 40.3% in the human papillomavirus (HPV) testing industry in 2025. It is likely to maintain its dominance throughout the forecast period.

The availability of robust diagnostic capabilities, particularly through advancements in dual-stain cytology using p16 and Ki-67 markers, is enhancing the efficiency and accuracy of cervical cancer screening. This method is superior to traditional Pap tests for managing HPV-positive results, as it can identify precisely which individuals are at high risk of developing precancerous lesions. In addition, the integration of AI tools like Cytoreader-V2 is expected to improve the process by reducing subjectivity and increasing specificity, which means fewer unnecessary follow-up procedures are required. Apart from technological advancements in diagnostic tools, the increasing adoption of HPV vaccines, such as Cervarix & Gardasil, in North America is projected to propel market growth during the forecast period.

GlaxoSmithKline offers Cervarix free of charge to low-income women in the age group of 19 to 25 without insurance through its Vaccines Access Program. Such initiatives have led to higher adoption of vaccines, which in turn will propel the demand for HPV testing in the region.

Asia Pacific Human Papillomavirus (HPV) Testing Market

Proactive Government Initiatives to Encourage HPV Vaccination to Favor Growth

The market for human papillomavirus (HPV) testing in the Asia Pacific is anticipated to register substantial growth between 2025 and 2032. Factors such as increasing demand for better healthcare infrastructure and supportive government initiatives are expected to boost the demand for HPV testing in countries such as India, China, Korea, and Japan. For example, in April 2025, the Indian government launched a comprehensive training program for doctors to advocate for the HPV vaccine. This initiative focuses on educating communities, countering misinformation, and encouraging discussions about the vaccine’s benefits. Approximately 11,000 members of the Federation of Obstetric and Gynecological Societies of India (FOGSI) underwent virtual training. This effort aligns with the government’s plan to include a domestically produced cervical cancer vaccine in the national immunization program.

Europe Human Papillomavirus (HPV) Testing Market

Rising Pharmaceutical Industry to Boost Vaccine Development & Ensure Stable Supply Chain

The global market for human papillomavirus is witnessing considerable growth, driven by increasing investments from prominent pharmaceutical companies, strategic collaborations, and supply chain expansion. Major players such as Merck & Co., GlaxoSmithKline, and others are investing heavily in manufacturing sites across Europe to cater to the increasing demand for the HPV vaccine. Merck, for example, has expanded its vaccine production facilities in Austria and the Netherlands. Moreover, several European Union (EU) countries, such as France and Germany, have long-term procurement agreements with Merck to ensure a stable vaccine supply.

Factors such as government collaborations, rising investments from the private-sector, supply chain advancements, and the rising pharma sector are projected to fuel the growth of the market in Europe during the forecast period.

Human Papillomavirus (HPV) Testing Market Competitive Landscape

The global market for human papillomavirus (HPV) testing is witnessing intense competition, with key players focusing on product innovations, strategic mergers and acquisitions, and collaborations to strengthen their market presence. Companies are developing high-sensitivity molecular assays, diagnostic tools using AI, and self-sampling kits to enhance screening accuracy and accessibility.

Additionally, partnerships between diagnostic firms and healthcare organizations are expanding testing capabilities in underserved regions. Major players like Roche, BD, Qiagen, and Hologic are investing in automated PCR-based HPV tests and digital cytology platforms to meet the growing demand for early detection and precision diagnostics.

For instance, according to studies, in March 2024, Hologic received FDA approval for its Aptima HPV assay on the Panther Fusion system, enabling faster, high-throughput molecular screening. This development enhances lab efficiency and testing accuracy, reinforcing the shift toward fully automated and integrated HPV diagnostic solutions. As more companies adopt screening using AI and telemedicine-based testing models, the market is set for continuous technological evolution, further driving adoption rates and improving global HPV screening programs.

Key Industry Developments

In February 2024, Roche launched a digital cytology platform that uses AI to enhance HPV diagnostics by improving sensitivity and reducing false-negative rates. This innovation integrates with Cobas HPV DNA testing, allowing automated detection of high-risk HPV strains and supporting laboratories in handling higher testing volumes with greater accuracy.
In June 2024, Qiagen collaborated with the UK’s National Health Service (NHS) to provide at-home HPV self-sampling kits, improving accessibility for women in underserved areas.
In January 2025, the U.S. Preventive Services Task Force proposed new guidelines allowing women aged 30 to 65 to opt for HPV testing every five years, using samples collected by themselves in a healthcare setting.

Companies Covered in Human Papillomavirus (HPV) Testing Market

F. Hoffman-La Roche Ltd.
Agilent Technologies, Inc.
Becton, Dickinson and Company
Qiagen N.V.
Thermo Fisher Scientific Inc.
Abbott Laboratories
Hologic Inc.
Cepheid Inc.
Seegene Inc.
Takara Bio Inc.
DaAn Gene Co., Ltd. of Sun Yat-Sen University
Promega Corporation
Greiner Bio-One International GmbH (Greiner Holding AG)
Enzo Biochem Inc.
Norgen Biotek Corp.
DiagCor Bioscience Inc Ltd
Hybribio Limited
Zytovision GmbH
Arbor Vita Corporation
Medical & Biological Laboratories Co., Ltd
Fujirebio Diagnostics, Inc.

Frequently Asked Questions

The market is set to reach US$ 1,400 Mn in 2025.

The industry will likely be valued at US$ 2,816 Mn in 2032.

The industry is set to surge at a CAGR of 10.5% through 2032.

Qiagen N.V., Cepheid Inc., and Hologic Inc., are a few key brands.

North America is anticipated to hold the largest share in the market in 2025.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Human Papillomavirus Testing Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. Macro-Economic Factors
  1. Global Sectorial Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Regulatory Landscape
2. Product Adoption Analysis
3. Value Chain Analysis
4. Key Deals and Mergers
5. PESTLE Analysis
6. Porter’s Five Force Analysis
Global Human Papillomavirus Testing Market Outlook:
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2032
3. Global Human Papillomavirus Testing Market Outlook: Product
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Product, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
    1. DNA-based Test
    2. RNA-based Test
  4. Market Attractiveness Analysis: Product
4. Global Human Papillomavirus Testing Market Outlook: Application
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Application, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
    1. Molecular Diagnostics
    2. Research Use
  4. Market Attractiveness Analysis: Application
5. Global Human Papillomavirus Testing Market Outlook: End User
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By End User, 2019 - 2024
  3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
    1. Hospitals
    2. Clinics
    3. Diagnostic Centers
    4. Research Institutes
  4. Market Attractiveness Analysis: End User
Global Human Papillomavirus Testing Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2024
3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. U.S.
  2. Canada
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
Europe Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
East Asia Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
South Asia & Oceania Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
Latin America Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
Middle East & Africa Human Papillomavirus Testing Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Product
  3. By Application
  4. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. DNA-based Test
  2. RNA-based Test
5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2024 - 2032
  1. Molecular Diagnostics
  2. Research Use
6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Clinics
  3. Diagnostic Centers
  4. Research Institutes
7. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. F. Hoffmann-La Roche Ltd.
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Agilent Technologies, Inc.
  3. Becton, Dickinson and Company
  4. Qiagen N.V.
  5. Thermo Fisher Scientific Inc.
  6. Abbott Laboratories
  7. Hologic Inc.
  8. Cepheid Inc.
  9. Seegene Inc.
  10. Takara Bio Inc.
  11. DaAn Gene Co., Ltd. of Sun Yat-Sen University
  12. Promega Corporation
  13. Greiner Bio-One International GmbH (Greiner Holding AG)
  14. Enzo Biochem Inc.
  15. Norgen Biotek Corp.
  16. DiagCor Bioscience Inc Ltd
  17. Hybribio Limited
  18. Zytovision GmbH
  19. Arbor Vita Corporation
  20. Medical & Biological Laboratories Co., Ltd
  21. Fujirebio Diagnostics, Inc.
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Report Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn/Mn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Application End User Region
Competitive Analysis	F. Hoffman-La Roche Ltd. Agilent Technologies, Inc. Becton, Dickinson and Company Qiagen N.V. Thermo Fisher Scientific Inc. Abbott Laboratories Hologic Inc. Cepheid Inc. Seegene Inc. Takara Bio Inc. DaAn Gene Co., Ltd. of Sun Yat-Sen University Promega Corporation Greiner Bio-One International GmbH (Greiner Holding AG) Enzo Biochem Inc. Norgen Biotek Corp. DiagCor Bioscience Inc Ltd Hybribio Limited Zytovision GmbH Arbor Vita Corporation Medical & Biological Laboratories Co., Ltd Fujirebio Diagnostics, Inc.
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Report Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Bn/Mn, Volume: As applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Application End User Region
Competitive Analysis	F. Hoffman-La Roche Ltd. Agilent Technologies, Inc. Becton, Dickinson and Company Qiagen N.V. Thermo Fisher Scientific Inc. Abbott Laboratories Hologic Inc. Cepheid Inc. Seegene Inc. Takara Bio Inc. DaAn Gene Co., Ltd. of Sun Yat-Sen University Promega Corporation Greiner Bio-One International GmbH (Greiner Holding AG) Enzo Biochem Inc. Norgen Biotek Corp. DiagCor Bioscience Inc Ltd Hybribio Limited Zytovision GmbH Arbor Vita Corporation Medical & Biological Laboratories Co., Ltd Fujirebio Diagnostics, Inc.
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Human Papillomavirus (HPV) Testing Market Size, Share, and Growth Forecast for 2025-2032

Human Papillomavirus (HPV) Testing Market by Product (DNA-based Test, RNA-based Test), Application (Molecular Diagnostics, Research Use), End User (Hospitals, Clinics, Diagnostics Centers, Research Institutes), and Regional Analysis